Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine Targets

A vaccine targeting HER2, a nonmutated but overexpressed tumor antigen, readily primed T cells for ex vivo expansion and adoptive transfer with minimal toxicity. This regimen led to intramolecular epitope spreading in a majority of patients and offers a treatment modality that may improve outcomes f...

Descripción completa

Detalles Bibliográficos
Autores principales: Crosby, Erika J., Hartman, Zachary C., Lyerly, H. Kim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
CCR Translations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472089/
https://www.ncbi.nlm.nih.gov/pubmed/37428103
http://dx.doi.org/10.1158/1078-0432.CCR-23-1244
_version_ 1785099999449710592
author Crosby, Erika J.
Hartman, Zachary C.
Lyerly, H. Kim
author_facet Crosby, Erika J.
Hartman, Zachary C.
Lyerly, H. Kim
author_sort Crosby, Erika J.
collection PubMed
description A vaccine targeting HER2, a nonmutated but overexpressed tumor antigen, readily primed T cells for ex vivo expansion and adoptive transfer with minimal toxicity. This regimen led to intramolecular epitope spreading in a majority of patients and offers a treatment modality that may improve outcomes for patients with metastatic breast cancer expressing HER2. See related article by Disis et al., p. 3362
format Online
Article
Text
id pubmed-10472089
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-104720892023-09-02 Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine Targets Crosby, Erika J. Hartman, Zachary C. Lyerly, H. Kim Clin Cancer Res CCR Translations A vaccine targeting HER2, a nonmutated but overexpressed tumor antigen, readily primed T cells for ex vivo expansion and adoptive transfer with minimal toxicity. This regimen led to intramolecular epitope spreading in a majority of patients and offers a treatment modality that may improve outcomes for patients with metastatic breast cancer expressing HER2. See related article by Disis et al., p. 3362 American Association for Cancer Research 2023-09-01 2023-07-10 /pmc/articles/PMC10472089/ /pubmed/37428103 http://dx.doi.org/10.1158/1078-0432.CCR-23-1244 Text en ©2023 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
spellingShingle CCR Translations
Crosby, Erika J.
Hartman, Zachary C.
Lyerly, H. Kim
Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine Targets
title Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine Targets
title_full Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine Targets
title_fullStr Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine Targets
title_full_unstemmed Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine Targets
title_short Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine Targets
title_sort beyond neoantigens: antigens derived from tumor drivers as cancer vaccine targets
topic CCR Translations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472089/
https://www.ncbi.nlm.nih.gov/pubmed/37428103
http://dx.doi.org/10.1158/1078-0432.CCR-23-1244
work_keys_str_mv AT crosbyerikaj beyondneoantigensantigensderivedfromtumordriversascancervaccinetargets
AT hartmanzacharyc beyondneoantigensantigensderivedfromtumordriversascancervaccinetargets
AT lyerlyhkim beyondneoantigensantigensderivedfromtumordriversascancervaccinetargets

Ejemplares similares